Imagine a scenario where one in four seniors with dementia is given medications that could actually harm them—drugs linked to falls, confusion, and even hospitalization. This is the alarming reality uncovered by a new study, despite years of clinical guidelines warning against such practices. But here's where it gets controversial: while overall prescriptions for these risky medications have declined, they're still being given to the very people who are most vulnerable to their side effects—older adults with cognitive impairment.
Published in the prestigious journal JAMA, the research reveals that over a nine-year period, prescriptions for these brain-altering medications dropped from 20% to 16% among all Medicare beneficiaries. However, the study found that 25% of individuals with dementia—a group already at heightened risk—continue to receive these drugs. And this is the part most people miss: over two-thirds of these prescriptions lacked a clear medical justification in 2021, raising serious concerns about inappropriate and potentially harmful prescribing practices.
Dr. John N. Mafi, a senior author of the study and associate professor at UCLA’s David Geffen School of Medicine, noted, 'These results highlight significant opportunities to improve care for millions of older Americans.' The medications in question include antidepressants with strong anticholinergic properties, antipsychotics, barbiturates, benzodiazepines, and non-benzodiazepine hypnotics—all known to affect the central nervous system (CNS).
Here’s a breakdown of the prescribing trends by medication class:
- Benzodiazepines: Declined from 11.4% to 9.1%.
- Nonbenzodiazepine hypnotics (sleep drugs): Fell from 7.4% to 2.9%.
- Antipsychotics: Surprisingly, prescriptions rose from 2.6% to 3.6%.
- Anticholinergic antidepressants: Remained steady at 2.6%.
- Barbiturates: Dropped slightly from 0.4% to 0.3%.
While the overall decline in prescriptions is encouraging, the persistence of these practices among vulnerable populations is deeply troubling. Is it ethical to continue prescribing these medications without clear clinical justification? And what alternatives should be explored to ensure safer care for seniors with dementia?
Dr. Annie Yang, who led the study, emphasizes the importance of patient-physician collaboration: 'Older patients and their caregivers should work closely with doctors to ensure these medications are truly necessary. When they’re not, tapering or stopping them could be a safer option.'
The study does have limitations, including the lack of Medicare Advantage data and a focus on prescribing prevalence rather than cumulative exposure. Yet, its findings are a stark reminder of the need for better oversight and personalized care in treating older adults with cognitive impairment.
What do you think? Are these prescribing practices a necessary evil, or is there a systemic issue that needs addressing? Share your thoughts in the comments—let’s spark a conversation that could lead to real change.
